{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:15:33Z","timestamp":1791238533632,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CIBERONC CB16\/12\/00234 and PMP22\/00064"],"award-info":[{"award-number":["CIBERONC CB16\/12\/00234 and PMP22\/00064"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CIBERONC CB16\/12\/00234 and PMP22\/00064"],"award-info":[{"award-number":["CIBERONC CB16\/12\/00234 and PMP22\/00064"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CIBERONC CB16\/12\/00234 and PMP22\/00064"],"award-info":[{"award-number":["CIBERONC CB16\/12\/00234 and PMP22\/00064"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CIBERONC CB16\/12\/00234 and PMP22\/00064"],"award-info":[{"award-number":["CIBERONC CB16\/12\/00234 and PMP22\/00064"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CIBERONC CB16\/12\/00234 and PMP22\/00064"],"award-info":[{"award-number":["CIBERONC CB16\/12\/00234 and PMP22\/00064"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CIBERONC CB16\/12\/00234 and PMP22\/00064"],"award-info":[{"award-number":["CIBERONC CB16\/12\/00234 and PMP22\/00064"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["AGAUR 2021SGR01112 and CERCA Program"],"award-info":[{"award-number":["AGAUR 2021SGR01112 and CERCA Program"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["AGAUR 2021SGR01112 and CERCA Program"],"award-info":[{"award-number":["AGAUR 2021SGR01112 and CERCA Program"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["AGAUR 2021SGR01112 and CERCA Program"],"award-info":[{"award-number":["AGAUR 2021SGR01112 and CERCA Program"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["AGAUR 2021SGR01112 and CERCA Program"],"award-info":[{"award-number":["AGAUR 2021SGR01112 and CERCA Program"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["AGAUR 2021SGR01112 and CERCA Program"],"award-info":[{"award-number":["AGAUR 2021SGR01112 and CERCA Program"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["AECC Investigador"],"award-info":[{"award-number":["AECC Investigador"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["PID2020-112595RB-I00, AEI\/10.13039\/501100011033"],"award-info":[{"award-number":["PID2020-112595RB-I00, AEI\/10.13039\/501100011033"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["PID2020-112595RB-I00, AEI\/10.13039\/501100011033"],"award-info":[{"award-number":["PID2020-112595RB-I00, AEI\/10.13039\/501100011033"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["PID2020-112595RB-I00, AEI\/10.13039\/501100011033"],"award-info":[{"award-number":["PID2020-112595RB-I00, AEI\/10.13039\/501100011033"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["PID2020-112595RB-I00, AEI\/10.13039\/501100011033"],"award-info":[{"award-number":["PID2020-112595RB-I00, AEI\/10.13039\/501100011033"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Constitutional primary monoallelic promoter methylation of hereditary cancer genes, although rare, may explain early-onset cancers without family history. Also, promoter methylation of a hereditary cancer gene secondary to a genetic alteration in a methylation regulatory region can cause a hereditary cancer syndrome. This study investigates constitutional promoter methylation as mechanism of inactivation of cancer predisposition genes in genetically unsolved familial and\/or early-onset colorectal cancer (CRC) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Bisulfite-treated peripheral blood DNA from 46 early-onset\/familial CRC patients was analyzed using the Illumina Infinium MethylationEPIC BeadChip. One early-onset CRC patient exhibited constitutional, likely monoallelic, methylation of CpG island 102 in\n                      <jats:italic>LTBP4<\/jats:italic>\n                      , a gene involved in TGF-\u03b2 signaling. Somatic methylation of this CpG island is common in CRC, and correlates with\n                      <jats:italic>LTBP4<\/jats:italic>\n                      downregulation.\n                      <jats:italic>LTBP4<\/jats:italic>\n                      double knockout mice develop colorectal adenomas and carcinomas, supporting the role\u00a0of this gene in CRC predisposition. No\u00a0additional cases with constitutional\n                      <jats:italic>LTBP4<\/jats:italic>\n                      CpG island 102 methylation or enrichment of deleterious\n                      <jats:italic>LTBP4<\/jats:italic>\n                      variants in CRC patients compared to controls were found. Another early-onset CRC patient exhibited mosaic\n                      <jats:italic>BRCA1<\/jats:italic>\n                      promoter methylation, typically associated with increased breast and ovarian cancer risk. No somatic second hit in\n                      <jats:italic>BRCA1<\/jats:italic>\n                      was detected in the patient\u2019s tumor, and homologous recombination deficiency-associated features were inconclusive.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our findings suggest that constitutional methylation of\n                      <jats:italic>LTBP4<\/jats:italic>\n                      CpG island 102 may be associated with increased CRC risk. Identification of additional cases is needed to confirm the existence of a novel CRC predisposition syndrome driven by epigenetic inactivation of\n                      <jats:italic>LTBP4<\/jats:italic>\n                      , potentially also linked to other clinical phenotypes associated with\n                      <jats:italic>LTBP4<\/jats:italic>\n                      deficiency, such as pulmonary emphysema. Whether constitutional\n                      <jats:italic>BRCA1<\/jats:italic>\n                      methylation contributes to CRC risk remains to be determined.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13148-025-01924-x","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:25:39Z","timestamp":1762341939000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Constitutional epimutations in LTBP4, a component of the TGF-\u03b2 signaling, and in BRCA1, as potential drivers of early-onset colorectal cancer"],"prefix":"10.1186","volume":"17","author":[{"given":"Mariona","family":"Terradas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Mur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco D.","family":"Mor\u00f3n-Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pol","family":"Mengod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara M. L.","family":"L\u00f6ffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah C.","family":"Helderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diantha","family":"Terlouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Sanju\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Bousquets-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julen","family":"Viana-Errasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xose S.","family":"Puente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Capell\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"van Wezel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob Nikolas","family":"Kather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conxi","family":"L\u00e1zaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"issue":"3","key":"1924_CR1","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1053\/j.gastro.2014.06.009","volume":"147","author":"TT Nieminen","year":"2014","unstructured":"Nieminen TT, O\u2019Donohue MF, Wu Y, et al. Germline mutation of RPS20, encoding a ribosomal protein, causes predisposition to hereditary nonpolyposis colorectal carcinoma without DNA mismatch repair deficiency. Gastroenterology. 2014;147(3):595\u20138. https:\/\/doi.org\/10.1053\/j.gastro.2014.06.009.","journal-title":"Gastroenterology"},{"issue":"1","key":"1924_CR2","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1186\/s12885-023-11328-w","volume":"23","author":"Z Feng","year":"2023","unstructured":"Feng Z, Yang X, Tian M, et al. BRCA genes as candidates for colorectal cancer genetic testing panel: systematic review and meta-analysis. BMC Cancer. 2023;23(1):807. https:\/\/doi.org\/10.1186\/s12885-023-11328-w.","journal-title":"BMC Cancer"},{"issue":"11","key":"1924_CR3","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1136\/jmg-2022-108984","volume":"60","author":"L Valle","year":"2023","unstructured":"Valle L, Katz LH, Latchford A, et al. Position statement of the International Society for Gastrointestinal Hereditary Tumours (InSiGHT) on APC I1307K. J Med Genet. 2023;60(11):1035\u201343.\u00a0https:\/\/doi.org\/10.1136\/jmg-2022-108984.","journal-title":"J Med Genet"},{"key":"1924_CR4","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/gim.2018.12","volume":"20","author":"BW Katona","year":"2018","unstructured":"Katona BW, Yurgelun MB, Garber JE, et al. A counseling framework for moderate-penetrance colorectal cancer susceptibility genes. Genet Med. 2018;20:1324\u20137. https:\/\/doi.org\/10.1038\/gim.2018.12.","journal-title":"Genet Med"},{"issue":"6","key":"1924_CR5","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1136\/gutjnl-2020-321825","volume":"70","author":"M Terradas","year":"2021","unstructured":"Terradas M, Mur P, Belhadj S, et al. TP53, a gene for colorectal cancer predisposition in the absence of Li-Fraumeni-associated phenotypes. Gut. 2021;70(6):1139\u201346. https:\/\/doi.org\/10.1136\/gutjnl-2020-321825.","journal-title":"Gut"},{"issue":"4","key":"1924_CR6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1158\/1940-6207.CAPR-20-0448","volume":"14","author":"MJ Hall","year":"2021","unstructured":"Hall MJ, Bernhisel R, Hughes E, et al. Germline pathogenic variants in the ataxia telangiectasia mutated (ATM) gene are associated with high and moderate risks for multiple cancers. Cancer Prev Res (Phila). 2021;14(4):433\u201340. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-20-0448.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"6","key":"1924_CR7","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.3390\/jcm9061954","volume":"9","author":"M Terradas","year":"2020","unstructured":"Terradas M, Capell\u00e1 G, Valle L. Dominantly Inherited Hereditary Nonpolyposis Colorectal Cancer Not Caused by MMR Genes. J Clin Med. 2020;9(6):1954.\u00a0https:\/\/doi.org\/10.3390\/jcm9061954.","journal-title":"J Clin Med"},{"issue":"10","key":"1924_CR8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/nrc4001","volume":"15","author":"MP Hitchins","year":"2015","unstructured":"Hitchins MP. Constitutional epimutation as a mechanism for cancer causality and heritability? Nat Rev Cancer. 2015;15(10):625\u201334. https:\/\/doi.org\/10.1038\/nrc4001.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"1924_CR9","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1001\/jamaoncol.2022.3846","volume":"8","author":"PE L\u00f8nning","year":"2022","unstructured":"L\u00f8nning PE, Nikolaienko O, Pan K, et al. Constitutional BRCA1 methylation and risk of incident triple-negative breast cancer and high-grade serous ovarian cancer. JAMA Oncol. 2022;8(11):1579\u201387. https:\/\/doi.org\/10.1001\/jamaoncol.2022.3846.","journal-title":"JAMA Oncol"},{"issue":"3","key":"1924_CR10","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.yexmp.2018.11.006","volume":"105","author":"CM Scott","year":"2018","unstructured":"Scott CM, Wong EM, Joo JE, et al. Genome-wide DNA methylation assessment of \u2018BRCA1-like\u2019 early-onset breast cancer: data from the Australian Breast Cancer family registry. Exp Mol Pathol. 2018;105(3):404\u201310. https:\/\/doi.org\/10.1016\/j.yexmp.2018.11.006.","journal-title":"Exp Mol Pathol"},{"issue":"1","key":"1924_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1158\/1940-6207.CAPR-10-0212","volume":"4","author":"EM Wong","year":"2011","unstructured":"Wong EM, Southey MC, Fox SB, et al. Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prev Res (Phila). 2011;4(1):23\u201333. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-10-0212.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"21","key":"1924_CR12","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1093\/hmg\/dds308","volume":"21","author":"T Hansmann","year":"2012","unstructured":"Hansmann T, Pliushch G, Leubner M, et al. Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer. Hum Mol Genet. 2012;21(21):4669\u201379. https:\/\/doi.org\/10.1093\/hmg\/dds308.","journal-title":"Hum Mol Genet"},{"issue":"24","key":"1924_CR13","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1001\/jama.2010.1877","volume":"304","author":"KL Bennett","year":"2010","unstructured":"Bennett KL, Mester J, Eng C. Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome. JAMA. 2010;304(24):2724\u201331. https:\/\/doi.org\/10.1001\/jama.2010.1877.","journal-title":"JAMA"},{"issue":"1","key":"1924_CR14","doi-asserted-by":"publisher","first-page":"btac830","DOI":"10.1093\/bioinformatics\/btac830","volume":"39","author":"JT Robinson","year":"2023","unstructured":"Robinson JT, Thorvaldsdottir H, Turner D, Mesirov JP. igv.js: an embeddable JavaScript implementation of the integrative genomics viewer (IGV). Bioinformatics. 2023;39(1):btac830.\u00a0https:\/\/doi.org\/10.1093\/bioinformatics\/btac830.","journal-title":"Bioinformatics"},{"issue":"1","key":"1924_CR15","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41597-022-01697-5","volume":"9","author":"A D\u00edez-Villanueva","year":"2022","unstructured":"D\u00edez-Villanueva A, Sanz-Pamplona R, Sol\u00e9 X, et al. COLONOMICS - integrative omics data of one hundred paired normal-tumoral samples from colon cancer patients. Sci Data. 2022;9(1):595. https:\/\/doi.org\/10.1038\/s41597-022-01697-5.","journal-title":"Sci Data"},{"key":"1924_CR16","doi-asserted-by":"publisher","unstructured":"Moreno Aguado V, Sanz Pamplona R, D\u00edez Villanueva A. Data from: Colonomics: integrative omics data of one hundred paired normal-tumoral samples from colon cancer patients. 2022;V2. Deposited 2022\u201303\u201322 14:12:28.532. https:\/\/doi.org\/10.34810\/data169","DOI":"10.34810\/data169"},{"key":"1924_CR17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/978-1-61779-270-0_17","volume":"780","author":"I Ibragimova","year":"2011","unstructured":"Ibragimova I, Cairns P. Assays for hypermethylation of the BRCA1 gene promoter in tumor cells to predict sensitivity to PARP-inhibitor therapy. Methods Mol Biol. 2011;780:277\u201391. https:\/\/doi.org\/10.1007\/978-1-61779-270-0_17.","journal-title":"Methods Mol Biol"},{"issue":"12","key":"1924_CR18","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/j.ajhg.2022.10.013","volume":"109","author":"V Pejaver","year":"2022","unstructured":"Pejaver V, Byrne AB, Feng BJ, et al. Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3\/BP4 criteria. Am J Hum Genet. 2022;109(12):2163\u201377. https:\/\/doi.org\/10.1016\/j.ajhg.2022.10.013.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"1924_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41698-023-00365-0","volume":"7","author":"OL Saldanha","year":"2023","unstructured":"Saldanha OL, Loeffler CML, Niehues JM, et al. Self-supervised attention-based deep learning for pan-cancer mutation prediction from histopathology. NPJ Precis Oncol. 2023;7(1):35. https:\/\/doi.org\/10.1038\/s41698-023-00365-0.","journal-title":"NPJ Precis Oncol"},{"key":"1924_CR20","doi-asserted-by":"publisher","DOI":"10.1101\/2023.03.08.23286975","author":"CML Loeffler","year":"2023","unstructured":"Loeffler CML, El Nahhas OSM, Muti HS, et al. Direct prediction of Homologous Recombination Deficiency from routine histology in ten different tumor types with attention-based Multiple Instance Learning: a development and validation study. medRxiv. 2023. https:\/\/doi.org\/10.1101\/2023.03.08.23286975.","journal-title":"medRxiv"},{"issue":"1","key":"1924_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41698-022-00276-6","volume":"6","author":"E Rempel","year":"2022","unstructured":"Rempel E, Kluck K, Beck S, et al. Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD). NPJ Precis Oncol. 2022;6(1):36. https:\/\/doi.org\/10.1038\/s41698-022-00276-6.","journal-title":"NPJ Precis Oncol"},{"issue":"2","key":"1924_CR22","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s43018-020-0027-5","volume":"1","author":"A Degasperi","year":"2020","unstructured":"Degasperi A, Amarante TD, Czarnecki J, et al. A practical framework and online tool for mutational signature analyses show inter-tissue variation and driver dependencies. Nat Cancer. 2020;1(2):249\u201363. https:\/\/doi.org\/10.1038\/s43018-020-0027-5.","journal-title":"Nat Cancer"},{"issue":"12","key":"1924_CR23","doi-asserted-by":"publisher","first-page":"btad756","DOI":"10.1093\/bioinformatics\/btad756","volume":"39","author":"M D\u00edaz-Gay","year":"2023","unstructured":"D\u00edaz-Gay M, Vangara R, Barnes M, et al. Assigning mutational signatures to individual samples and individual somatic mutations with SigProfilerAssignment. Bioinformatics. 2023;39(12):btad756.\u00a0https:\/\/doi.org\/10.1093\/bioinformatics\/btad756.","journal-title":"Bioinformatics"},{"issue":"1","key":"1924_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S2468-1253(23)00240-6","volume":"9","author":"L Valle","year":"2023","unstructured":"Valle L, Monahan KJ. Genetic predisposition to gastrointestinal polyposis: syndromes, tumour features, genetic testing, and clinical management. Lancet Gastroenterol Hepatol. 2023;9(1):68\u201382. https:\/\/doi.org\/10.1016\/S2468-1253(23)00240-6.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"1924_CR25","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1038\/s41467-019-09775-w","volume":"10","author":"PJ Law","year":"2019","unstructured":"Law PJ, Timofeeva M, Fernandez-Rozadilla C, et al. Association analyses identify 31 new risk loci for colorectal cancer susceptibility. Nat Commun. 2019;10(1):2154. https:\/\/doi.org\/10.1038\/s41467-019-09775-w.","journal-title":"Nat Commun"},{"issue":"6","key":"1924_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1002105","volume":"7","author":"IP Tomlinson","year":"2011","unstructured":"Tomlinson IP, Carvajal-Carmona LG, Dobbins SE, et al. Multiple common susceptibility variants near BMP pathway loci GREM1, BMP4, and BMP2 explain part of the missing heritability of colorectal cancer. PLoS Genet. 2011;7(6): e1002105. https:\/\/doi.org\/10.1371\/journal.pgen.1002105.","journal-title":"PLoS Genet"},{"issue":"17","key":"1924_CR27","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1101\/gad.229102","volume":"16","author":"A Sterner-Kock","year":"2002","unstructured":"Sterner-Kock A, Thorey IS, Koli K, et al. Disruption of the gene encoding the latent transforming growth factor-beta binding protein 4 (LTBP-4) causes abnormal lung development, cardiomyopathy, and colorectal cancer. Genes Dev. 2002;16(17):2264\u201373. https:\/\/doi.org\/10.1101\/gad.229102.","journal-title":"Genes Dev"},{"key":"1924_CR28","unstructured":"Callewaert B, Urban Z. LTBP4-Related Cutis Laxa. GeneReviews\u00ae [Internet]. University of Washington, Seattle; 2016 [updated 2023]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK343782\/"},{"issue":"5","key":"1924_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065614","volume":"8","author":"I Bultmann","year":"2013","unstructured":"Bultmann I, Conradi A, Kretschmer C, Sterner-Kock A. Latent transforming growth factor \u03b2-binding protein 4 is downregulated in esophageal cancer via promoter methylation. PLoS ONE. 2013;8(5): e65614. https:\/\/doi.org\/10.1371\/journal.pone.0065614.","journal-title":"PLoS ONE"},{"issue":"5","key":"1924_CR30","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s13402-011-0023-y","volume":"34","author":"C Kretschmer","year":"2011","unstructured":"Kretschmer C, Conradi A, Kemmner W, Sterner-Kock A. Latent transforming growth factor binding protein 4 (LTBP4) is downregulated in mouse and human DCIS and mammary carcinomas. Cell Oncol (Dordr). 2011;34(5):419\u201334. https:\/\/doi.org\/10.1007\/s13402-011-0023-y.","journal-title":"Cell Oncol (Dordr)"},{"issue":"6","key":"1924_CR31","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/j.1600-0463.2007.apm_453.x","volume":"115","author":"S Mauel","year":"2007","unstructured":"Mauel S, Kruse B, Etschmann B, et al. Latent transforming growth factor binding protein 4 (LTBP-4) is downregulated in human mammary adenocarcinomas in vitro and in vivo. APMIS. 2007;115(6):687\u2013700. https:\/\/doi.org\/10.1111\/j.1600-0463.2007.apm_453.x.","journal-title":"APMIS"},{"key":"1924_CR32","doi-asserted-by":"publisher","first-page":"7007","DOI":"10.2147\/OTT.S246766","volume":"13","author":"X Yang","year":"2020","unstructured":"Yang X, Ye X, Zhang L, Zhang X, Shu P. Disruption of LTBP4 induced activated TGF\u03b21, immunosuppression signal and promoted pulmonary metastasis in hepatocellular carcinoma. Onco Targets Ther. 2020;13:7007\u201317. https:\/\/doi.org\/10.2147\/OTT.S246766.","journal-title":"Onco Targets Ther"},{"issue":"14","key":"1924_CR33","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1200\/JCO.21.02112","volume":"40","author":"S Li","year":"2022","unstructured":"Li S, Silvestri V, Leslie G, et al. Cancer risks associated with BRCA1 and BRCA2 pathogenic variants. J Clin Oncol. 2022;40(14):1529\u201341. https:\/\/doi.org\/10.1200\/JCO.21.02112.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1924_CR34","doi-asserted-by":"publisher","first-page":"326","DOI":"10.7326\/M17-0101","volume":"168","author":"PE L\u00f8nning","year":"2018","unstructured":"L\u00f8nning PE, Berge EO, Bj\u00f8rnslett M, et al. White blood cell BRCA1 promoter methylation status and ovarian cancer risk. Ann Intern Med. 2018;168(5):326\u201334. https:\/\/doi.org\/10.7326\/M17-0101.","journal-title":"Ann Intern Med"},{"issue":"5","key":"1924_CR35","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1002\/ijc.32655","volume":"146","author":"K Prajzendanc","year":"2020","unstructured":"Prajzendanc K, Domaga\u0142a P, Hybiak J, et al. BRCA1 promoter methylation in peripheral blood is associated with the risk of triple-negative breast cancer. Int J Cancer. 2020;146(5):1293\u20138. https:\/\/doi.org\/10.1002\/ijc.32655.","journal-title":"Int J Cancer"},{"issue":"1","key":"1924_CR36","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1038\/s41467-020-17537-2","volume":"11","author":"D Glodzik","year":"2020","unstructured":"Glodzik D, Bosch A, Hartman J, et al. Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers. Nat Commun. 2020;11(1):3747. https:\/\/doi.org\/10.1038\/s41467-020-17537-2.","journal-title":"Nat Commun"},{"issue":"2","key":"1924_CR37","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ajhg.2018.07.002","volume":"103","author":"DGR Evans","year":"2018","unstructured":"Evans DGR, van Veen EM, Byers HJ, et al. A dominantly inherited 5\u2019 UTR variant causing methylation-associated silencing of BRCA1 as a cause of breast and ovarian cancer. Am J Hum Genet. 2018;103(2):213\u201320. https:\/\/doi.org\/10.1016\/j.ajhg.2018.07.002.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"1924_CR38","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1200\/JCO.24.01146","volume":"43","author":"I Allen","year":"2025","unstructured":"Allen I, Hassan H, Walburga Y, et al. Second primary cancer risks after breast cancer in BRCA1 and BRCA2 pathogenic variant carriers. J Clin Oncol. 2025;43(6):651\u201361. https:\/\/doi.org\/10.1200\/JCO.24.01146.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1924_CR39","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/cge.12497","volume":"87","author":"V Sopik","year":"2015","unstructured":"Sopik V, Phelan C, Cybulski C, Narod SA. BRCA1 and BRCA2 mutations and the risk for colorectal cancer. Clin Genet. 2015;87(5):411\u20138. https:\/\/doi.org\/10.1111\/cge.12497.","journal-title":"Clin Genet"},{"issue":"2","key":"1924_CR40","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/bjc.2013.741","volume":"110","author":"CM Phelan","year":"2014","unstructured":"Phelan CM, Iqbal J, Lynch HT, et al. Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study. Br J Cancer. 2014;110(2):530\u20134. https:\/\/doi.org\/10.1038\/bjc.2013.741.","journal-title":"Br J Cancer"},{"issue":"18","key":"1924_CR41","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1093\/jnci\/94.18.1365","volume":"94","author":"MS Brose","year":"2002","unstructured":"Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002;94(18):1365\u201372. https:\/\/doi.org\/10.1093\/jnci\/94.18.1365.","journal-title":"J Natl Cancer Inst"},{"issue":"25","key":"1924_CR42","doi-asserted-by":"publisher","first-page":"19092","DOI":"10.1074\/jbc.M110.104430","volume":"285","author":"T Saha","year":"2010","unstructured":"Saha T, Rih JK, Roy R, Ballal R, Rosen EM. Transcriptional regulation of the base excision repair pathway by BRCA1. J Biol Chem. 2010;285(25):19092\u2013105. https:\/\/doi.org\/10.1074\/jbc.M110.104430.","journal-title":"J Biol Chem"},{"issue":"3","key":"1924_CR43","doi-asserted-by":"publisher","DOI":"10.4161\/23723556.2014.979685","volume":"2","author":"E Alli","year":"2015","unstructured":"Alli E, Ford JM. BRCA1: a movement toward cancer prevention. Mol Cell Oncol. 2015;2(3): e979685. https:\/\/doi.org\/10.4161\/23723556.2014.979685.","journal-title":"Mol Cell Oncol"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-01924-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-025-01924-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-01924-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:25:41Z","timestamp":1762341941000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-025-01924-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1924"],"URL":"https:\/\/doi.org\/10.1186\/s13148-025-01924-x","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received the approvals of the Ethics Committee of the Bellvitge Biomedical Research Centre (IDIBELL, Spain) (Protocol PR073\/12), and the Medical Ethical Committee of the Leiden University Medical Centre (LUMC, The Netherlands) (Protocol P01.019).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"JNK declares consulting services for Bioptimus, France; Owkin, France; DoMore Diagnostics, Norway; Panakeia, UK; AstraZeneca, UK; Scailyte, Switzerland; Mindpeak, Germany; and MultiplexDx, Slovakia. Furthermore, he holds shares in StratifAI GmbH, Germany, Synagen GmbH, Germany, and has received a research grant by GSK, and has received honoraria by AstraZeneca, Bayer, Daiichi Sankyo, Eisai, Janssen, MSD, BMS, Roche, Pfizer, and Fresenius. The other authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"183"}}